Paper Details

  1. Home
  2. Paper Details

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: AscariE, BarbaranoL, BergonziC, BrugnatelliS, De PaoliA, Di StasiM, MoraO, PetriniM, PiccininiL, PivaN, RiccardiA, RinaldiE, TrottiG, UcciG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared two chemotherapy regimens for patients with advanced, previously treated multiple myeloma. Both regimens, cyclophosphamide with prednisone and interferon-alpha2b, and epirubicin with prednisone and interferon-alpha2b, showed similar effectiveness and low side effects. The overall response rate was 43%, with a median response duration of 5.9 months and a median survival of 14.1 months. These results are comparable to those achieved with more aggressive chemotherapy regimens, suggesting that these outpatient regimens may be a viable alternative.
Paper Details　
Original Abstract of the Article :
In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both reg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/bjc.1996.138

データ提供：米国国立医学図書館（NLM）

Less Toxic Treatment for Multiple Myeloma

The field of [oncology] is constantly striving to develop less toxic and more effective treatments for cancer. This study investigates the effectiveness of two poorly myelosuppressive chemotherapy regimens in treating advanced multiple myeloma (MM). The study used a [randomized controlled trial] design to compare the efficacy of cyclophosphamide and epirubicin, both combined with prednisone and interferon-alpha2b, in patients with advanced MM. The results demonstrate that both regimens exhibited low hematological toxicity and comparable clinical outcomes, offering a less toxic alternative to more aggressive chemotherapy schedules.

A New Approach for Cancer Treatment

The study's findings suggest that these poorly myelosuppressive regimens provide an effective treatment option for advanced MM with reduced side effects. The comparable clinical outcomes, including response rate and survival, to more aggressive regimens are a significant finding. This finding underscores the importance of exploring less toxic treatment options in oncology, especially for patients with advanced cancers.

A New Oasis in the Desert of Cancer Treatment

This study emphasizes the importance of finding less toxic treatment options for cancer. It's like finding an oasis in the desert of cancer treatment, offering a way to battle the disease without compromising patients' well-being.

Dr.Camel's Conclusion

This study provides a compelling argument for exploring less toxic treatment regimens for advanced multiple myeloma. The results offer hope for patients seeking effective treatment with minimal side effects. It's a reminder that research is constantly evolving in the field of oncology, offering new avenues for better patient care.
Date :
  1. Date Completed 1996-06-04
  2. Date Revised 2019-05-15
Further Info :

Pubmed ID

8611382

DOI: Digital Object Identifier

10.1038/bjc.1996.138

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.